Patents Assigned to Oxigene, Inc.
  • Tubulin binding ligands and corresponding prodrug constructs
    Patent number: 7091240
    Abstract: A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, phosphoramidates, and other prodrugs capable of demonstrating selective targeting and destruction of tumor cell vasculature.
    Type: Grant
    Filed: April 29, 2003
    Date of Patent: August 15, 2006
    Assignees: Oxigene, Inc., Baylor University
    Inventors: Kevin G. Pinney, Vani P. Mocharla, Zhi Chen, Charles M. Garner, Mallinath Hadimani, Raymond Kessler, James M. Dorsey, Klaus Edvardsen, David J. Chaplin, Joseph Prezioso, Usha Ghatak, legal representative, Anjan Ghatak, deceased
  • Methods for modulating tumor growth and metastasis
    Patent number: 7037906
    Abstract: Methods and pharmaceutical compositions for modulating tumor growth or metastasis are provided.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: May 2, 2006
    Assignees: Oxigene, Inc., Bristol-Myers Squibb, Inc.
    Inventor: Francis Y. Lee
  • Tubulin binding agents and corresponding prodrug constructs
    Patent number: 7001926
    Abstract: A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, phosphoramidates, and other prodrugs capable of demonstrating selective targeting and destruction of tumor cell vasculature.
    Type: Grant
    Filed: April 1, 2003
    Date of Patent: February 21, 2006
    Assignees: Oxigene, Inc., Baylor University
    Inventors: Kevin G. Pinney, Vani P. Mocharla, Zhi Chen, Usha R. Ghatak, legal representative, Mallinath Hadimani, Jimmy Kessler, James M. Dorsey, Klaus Edvardsen, David J. Chaplin, Joseph Prezioso, Anjan Ghatak, deceased
  • Functionalized stilbene derivatives as improved vascular targeting agents
    Patent number: 6919324
    Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: July 19, 2005
    Assignees: Oxigene, Inc., Baylor University
    Inventors: David J. Chaplin, Charles Manly Garner, III, Robert Ronald Kane, Kevin G. Pinney, Joseph Anthony Prezioso, Klaus Edvardsen
  • Efficient method of synthesizing combretastatin A-4 prodrugs
    Patent number: 6743937
    Abstract: Methods of synthesizing a phosphate ester of combretastatin A-4 and trans-isomers thereof in which combretastatin A-4 is reacted with dibenzylphosphite in the presence of carbon tetrabromide, or with 2,2,2-trichloroethyl phosphorodichloridate, to form a phosphate ester of combretastatin A-4 with protecting groups thereon.
    Type: Grant
    Filed: July 17, 2001
    Date of Patent: June 1, 2004
    Assignee: OxiGene, Inc.
    Inventors: Faye Seyedi, Jonathan Gale, Reem Haider, John Hoare, Amy Baldwin
  • Uses of nicotinamide adenine dinucleotide and its derivatives for treatment of malignant and infectious diseases
    Patent number: 6339073
    Abstract: This invention provides a method of killing tumor cells or microorganisms which comprises contacting the tumor cells or the microorganisms with an amount of nicotinamide adenine dinucleotide (NAD) or its analogs effective to increase clonogenic toxicity of cells. This invention also provides a method of killing tumor cells or microoganisms in a subject which comprises administering an amount of nicotinamide adenine dinucleotide or its analogs effective to increase clonogenic toxicity of cells to the subject.
    Type: Grant
    Filed: September 9, 1998
    Date of Patent: January 15, 2002
    Assignee: Oxigene, Inc.
    Inventor: Ronald W. Pero
  • N-acetyl 3-chloroprocainamide, acid addition salts thereof, and methods of use
    Patent number: 6100299
    Abstract: N-acetyl-3-chloroprocainamide, its acid addition salts, mixtures thereof, formulations containing the same for therapeutic administration to a human or other animal, and uses thereof in methods of inhibiting or killing tumor or cancer cells and in methods of treating inflammatory disorders.
    Type: Grant
    Filed: June 8, 1998
    Date of Patent: August 8, 2000
    Assignee: OXiGene, Inc.
    Inventor: Ronald W. Pero